Cite
HARVARD Citation
Friedman, C. et al. (2022). Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses. Journal for immunotherapy of cancer. 10 (1), p. . [Online].